Randhawa Simrat (CIK 1992260) reported 27 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-03). Recent activity: Buy DNTH (7,500 shares), Buy DNTH (6,249 shares), Buy DNTH (9,375 shares), Sell DNTH (2,600 shares), Sell DNTH (7,215 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 7,500 | $134,100 |
| 2026-09-03 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 6,249 | $136,041 |
| 2026-09-03 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 9,375 | $206,906 |
| 2026-09-03 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 2,600 | $273,494 |
| 2026-09-03 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 7,215 | $766,594 |
| 2026-09-03 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 13,309 | $1.4M |
| 2026-06-02 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 4,159 | $380,008 |
| 2026-06-02 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 6,908 | $123,515 |
| 2026-06-02 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 6,249 | $136,041 |
| 2026-06-02 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 9,375 | $206,906 |
| 2026-06-02 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 5,428 | $487,000 |
| 2026-06-02 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 16,943 | $1.5M |
| 2026-06-02 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 3,998 | $33,743 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 7,998 | $67,503 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 5,000 | $89,400 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 8,332 | $181,388 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 12,500 | $275,875 |
| 2026-03-13 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 33,830 | $2.8M |
| 2025-11-14 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 83,978 | $708,774 |
| 2025-11-14 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 3,529 | $63,099 |
| 2025-11-14 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 26,166 | $936,743 |
| 2025-11-14 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 42,765 | $1.6M |
| 2025-11-14 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Sell | 18,576 | $700,687 |
| 2025-11-14 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 40,287 | $720,332 |
| 2025-11-14 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | EVP, Head of R&D | Buy | 37,494 | $816,244 |
来源：SEC Form 4 申报文件 · 截至 2026-09-03